$COGT
Cogent Biosciences, Inc.

2024 Q4 Form 10-Q Financial Statement

#000095017024124712 Filed on November 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $11.80M
YoY Change 24.87%
% of Gross Profit
Research & Development $63.61M
YoY Change 26.91%
% of Gross Profit
Depreciation & Amortization $620.0K
YoY Change 6.9%
% of Gross Profit
Operating Expenses $63.61M
YoY Change 26.91%
Operating Profit -$75.41M
YoY Change 26.58%
Interest Expense $4.779M
YoY Change 13.79%
% of Operating Profit
Other Income/Expense, Net $4.780M
YoY Change 13.86%
Pretax Income -$70.63M
YoY Change 27.54%
Income Tax
% Of Pretax Income
Net Earnings -$70.63M
YoY Change 27.54%
Net Earnings / Revenue
Basic Earnings Per Share -$0.64
Diluted Earnings Per Share -$0.64
COMMON SHARES
Basic Shares Outstanding 110.5M 109.5M
Diluted Shares Outstanding 110.2M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $335.5M
YoY Change 20.24%
Cash & Equivalents $97.05M
Short-Term Investments $238.5M
Other Short-Term Assets $6.009M
YoY Change -12.91%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $341.5M
YoY Change 19.44%
LONG-TERM ASSETS
Property, Plant & Equipment $7.017M
YoY Change -18.81%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $10.03M
YoY Change -70.33%
Other Assets $4.862M
YoY Change 0.0%
Total Long-Term Assets $42.49M
YoY Change -38.86%
TOTAL ASSETS
Total Short-Term Assets $341.5M
Total Long-Term Assets $42.49M
Total Assets $384.0M
YoY Change 8.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $15.06M
YoY Change 52.62%
Accrued Expenses $37.68M
YoY Change 54.43%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $53.05M
YoY Change 52.79%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $16.31M
YoY Change -8.38%
Total Long-Term Liabilities $16.31M
YoY Change -8.38%
TOTAL LIABILITIES
Total Short-Term Liabilities $53.05M
Total Long-Term Liabilities $16.31M
Total Liabilities $69.36M
YoY Change 31.99%
SHAREHOLDERS EQUITY
Retained Earnings -$791.6M
YoY Change 44.11%
Common Stock $994.7M
YoY Change 25.55%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $314.7M
YoY Change
Total Liabilities & Shareholders Equity $384.0M
YoY Change 8.04%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$70.63M
YoY Change 27.54%
Depreciation, Depletion And Amortization $620.0K
YoY Change 6.9%
Cash From Operating Activities -$51.98M
YoY Change 36.91%
INVESTING ACTIVITIES
Capital Expenditures $280.0K
YoY Change 133.33%
Acquisitions
YoY Change
Other Investing Activities $60.47M
YoY Change -166.88%
Cash From Investing Activities $60.19M
YoY Change -166.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 624.0K
YoY Change -37.6%
NET CHANGE
Cash From Operating Activities -51.98M
Cash From Investing Activities 60.19M
Cash From Financing Activities 624.0K
Net Change In Cash 8.826M
YoY Change -106.92%
FREE CASH FLOW
Cash From Operating Activities -$51.98M
Capital Expenditures $280.0K
Free Cash Flow -$52.26M
YoY Change 37.21%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001622229
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38443
dei Entity Registrant Name
EntityRegistrantName
Cogent Biosciences, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-5308248
dei Entity Address Address Line1
EntityAddressAddressLine1
275 Wyman Street
dei Entity Address Address Line2
EntityAddressAddressLine2
3rd Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Waltham
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02451
dei City Area Code
CityAreaCode
(617)
dei Local Phone Number
LocalPhoneNumber
945-5576
dei Security12b Title
Security12bTitle
Common Stock, $0.001 Par Value
dei Trading Symbol
TradingSymbol
COGT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
110461729
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
97045000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
53229000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
238474000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
212481000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6009000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5061000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
341528000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
270771000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
10029000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
7460000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20580000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
21998000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7017000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8344000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4862000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4864000
CY2024Q3 us-gaap Assets
Assets
384016000
CY2023Q4 us-gaap Assets
Assets
313437000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
15061000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
10655000
CY2024Q3 cogt Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
36467000
CY2023Q4 cogt Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
26127000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1520000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1386000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
53048000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
38168000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
16309000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
17467000
CY2024Q3 us-gaap Liabilities
Liabilities
69357000
CY2023Q4 us-gaap Liabilities
Liabilities
55635000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
110458249
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
110458249
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
86124249
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
86124249
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
110000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
86000
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
994609000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
801059000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
896000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
246000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-791556000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-603624000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
314659000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
257802000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
384016000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
313437000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
63614000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
50127000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
170613000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
125036000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11800000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9453000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
31592000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
24866000
CY2024Q3 us-gaap Costs And Expenses
CostsAndExpenses
75414000
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
59580000
us-gaap Costs And Expenses
CostsAndExpenses
202205000
us-gaap Costs And Expenses
CostsAndExpenses
149902000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-75414000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-59580000
us-gaap Operating Income Loss
OperatingIncomeLoss
-202205000
us-gaap Operating Income Loss
OperatingIncomeLoss
-149902000
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
4779000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
4198000
us-gaap Investment Income Interest
InvestmentIncomeInterest
14229000
us-gaap Investment Income Interest
InvestmentIncomeInterest
9207000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
44000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
950000
CY2024Q3 cogt Change In Fair Value Of Contingent Value Right Liability
ChangeInFairValueOfContingentValueRightLiability
0
CY2023Q3 cogt Change In Fair Value Of Contingent Value Right Liability
ChangeInFairValueOfContingentValueRightLiability
0
cogt Change In Fair Value Of Contingent Value Right Liability
ChangeInFairValueOfContingentValueRightLiability
0
cogt Change In Fair Value Of Contingent Value Right Liability
ChangeInFairValueOfContingentValueRightLiability
-1700000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4780000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4198000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
14273000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
11857000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-70634000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-55382000
us-gaap Net Income Loss
NetIncomeLoss
-187932000
us-gaap Net Income Loss
NetIncomeLoss
-138045000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.64
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.64
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.64
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.64
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.85
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.85
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.79
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.79
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
110165580
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
110165580
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
86165951
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
86165951
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
101435402
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
101435402
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
77274580
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
77274580
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-70634000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-55382000
us-gaap Net Income Loss
NetIncomeLoss
-187932000
us-gaap Net Income Loss
NetIncomeLoss
-138045000
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1088000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-75000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
650000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-68000
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1088000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-75000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
650000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-68000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-69546000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-55457000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-187282000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-138113000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
257802000
CY2024Q1 cogt Issuance Of Preferred Stock And Common Stock Net Of Issuance Costs
IssuanceOfPreferredStockAndCommonStockNetOfIssuanceCosts
213416000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
356000
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-285000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9393000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-58348000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
422334000
CY2024Q2 cogt Change In Estimate On Private Placement Issuance Costs
ChangeInEstimateOnPrivatePlacementIssuanceCosts
129000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
109000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-153000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10012000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-58950000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
373223000
CY2024Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
561000
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
63000
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
1088000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10358000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-70634000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
314659000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
255735000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
313000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
132000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
120000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5850000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-38587000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
223563000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
102000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-113000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7163000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-44076000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
348428000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
731000
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
439000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-75000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8757000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-55382000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
302898000
us-gaap Profit Loss
ProfitLoss
-187932000
us-gaap Profit Loss
ProfitLoss
-138045000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1825000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1672000
us-gaap Share Based Compensation
ShareBasedCompensation
29763000
us-gaap Share Based Compensation
ShareBasedCompensation
21770000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1418000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1122000
cogt Change In Fair Value Of Contingent Value Right Liability
ChangeInFairValueOfContingentValueRightLiability
0
cogt Change In Fair Value Of Contingent Value Right Liability
ChangeInFairValueOfContingentValueRightLiability
-1700000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
5015000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
871000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
948000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2477000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
2000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
117000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4406000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4026000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
10295000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
5542000
cogt Increase Decrease In Operating Leases
IncreaseDecreaseInOperatingLeases
-1024000
cogt Increase Decrease In Operating Leases
IncreaseDecreaseInOperatingLeases
-476000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-147214000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-109554000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
498000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2481000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
242879000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
297888000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
219982000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
192056000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-23395000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-108313000
cogt Proceeds From Issuance Of Common Stock And Preferred Stock Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockAndPreferredStockNetOfOfferingCosts
213336000
cogt Proceeds From Issuance Of Common Stock And Preferred Stock Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockAndPreferredStockNetOfOfferingCosts
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
161819000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
917000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
752000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
172000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
965000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
214425000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
163536000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
43816000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-54331000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53229000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
141141000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
97045000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
86810000
cogt Offering Costs Included In Accounts Payable And Accrued Expenses
OfferingCostsIncludedInAccountsPayableAndAccruedExpenses
45000
cogt Offering Costs Included In Accounts Payable And Accrued Expenses
OfferingCostsIncludedInAccountsPayableAndAccruedExpenses
30000
cogt Property And Equipment Included In Accounts Payable And Accrued Expenses
PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses
0
cogt Property And Equipment Included In Accounts Payable And Accrued Expenses
PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses
51000
us-gaap Net Income Loss
NetIncomeLoss
-187900000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-791600000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#222222;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#222222;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Actual results may differ from those estimates or assumptions.</span></p>
CY2024Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
247607000
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
896000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
248503000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
219695000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
252000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
6000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
219941000
CY2024Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
0
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
9
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
34700000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0
CY2024Q3 cogt Debt Securities Available For Sale Credit Related Impairments Charges
DebtSecuritiesAvailableForSaleCreditRelatedImpairmentsCharges
0
CY2023 cogt Debt Securities Available For Sale Credit Related Impairments Charges
DebtSecuritiesAvailableForSaleCreditRelatedImpairmentsCharges
0
cogt Debt Securities Available For Sale Credit Related Impairments Charges
DebtSecuritiesAvailableForSaleCreditRelatedImpairmentsCharges
0
CY2024Q3 cogt Fair Value Assets Transfers Between Level One Two And Three
FairValueAssetsTransfersBetweenLevelOneTwoAndThree
0
CY2024Q3 cogt Fair Value Assets Transfers Between Level One Two And Three
FairValueAssetsTransfersBetweenLevelOneTwoAndThree
0
CY2023Q3 cogt Fair Value Assets Transfers Between Level One Two And Three
FairValueAssetsTransfersBetweenLevelOneTwoAndThree
0
CY2023Q3 cogt Fair Value Assets Transfers Between Level One Two And Three
FairValueAssetsTransfersBetweenLevelOneTwoAndThree
0
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7727000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9874000
CY2024Q3 cogt Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
20466000
CY2023Q4 cogt Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
10252000
CY2024Q3 cogt Accrued External Manufacturing Cost Current
AccruedExternalManufacturingCostCurrent
4312000
CY2023Q4 cogt Accrued External Manufacturing Cost Current
AccruedExternalManufacturingCostCurrent
3302000
CY2024Q3 cogt Accrued Professional And Consulting Services
AccruedProfessionalAndConsultingServices
3656000
CY2023Q4 cogt Accrued Professional And Consulting Services
AccruedProfessionalAndConsultingServices
2258000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
306000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
441000
CY2024Q3 cogt Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
36467000
CY2023Q4 cogt Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
26127000
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
213400000
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10358000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8757000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
29763000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
21770000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10358000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8757000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
29763000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
21770000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y4M13D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
600000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-70634000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-55382000
us-gaap Net Income Loss
NetIncomeLoss
-187932000
us-gaap Net Income Loss
NetIncomeLoss
-138045000
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-70634000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-55382000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-187932000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-138045000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
110165580
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
110165580
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
86165951
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
86165951
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
101435402
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
101435402
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
77274580
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
77274580
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.64
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.64
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.64
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.64
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.85
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.85
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.79
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.79
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
48499463
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
36635828
CY2024Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.01
us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
1
CY2024Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
300000
CY2023Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
200000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
1200000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
900000
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-124712-index-headers.html Edgar Link pending
0000950170-24-124712-index.html Edgar Link pending
0000950170-24-124712.txt Edgar Link pending
0000950170-24-124712-xbrl.zip Edgar Link pending
cogt-20240930.htm Edgar Link pending
cogt-20240930.xsd Edgar Link pending
cogt-ex31_1.htm Edgar Link pending
cogt-ex31_2.htm Edgar Link pending
cogt-ex32_1.htm Edgar Link pending
cogt-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img158370842_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
cogt-20240930_htm.xml Edgar Link completed
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable